[go: up one dir, main page]

MA33181B1 - Dérivés de pyrrolo [2,3-b]pyridine pour l'inhibition des kinases raf - Google Patents

Dérivés de pyrrolo [2,3-b]pyridine pour l'inhibition des kinases raf

Info

Publication number
MA33181B1
MA33181B1 MA34228A MA34228A MA33181B1 MA 33181 B1 MA33181 B1 MA 33181B1 MA 34228 A MA34228 A MA 34228A MA 34228 A MA34228 A MA 34228A MA 33181 B1 MA33181 B1 MA 33181B1
Authority
MA
Morocco
Prior art keywords
pyrrolo
pyridine
difluoro
carbonyl
phenyl
Prior art date
Application number
MA34228A
Other languages
Arabic (ar)
English (en)
Inventor
Prabha N Ibrahim
Wayne Spevak
Hanna Cho
Hongyao Zhu
Original Assignee
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plexxikon Inc filed Critical Plexxikon Inc
Publication of MA33181B1 publication Critical patent/MA33181B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION CONCERNE LE PROPANE-1-ACIDE SULFONIQUE {2,4-DIFLUORO-3-[5-(2-MÉTHOXY-PYRIMIDINE-5-YL)-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL]-PHÉNYL}-AMIDE, LE PROPANE-1-ACIDE SULFONIQUE [3-(5-CYANO-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL)-2,4-DIFLUORO-PHÉNYL]-AMIDE,LE PROPANE-1-ACIDE SULFONIQUE [3-(5-CYANO-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL)-2-FLUORO-PHÉNYL]-AMIDE, LE N-[3-(5-CYANO-1H-PYRROLO[2,3-B] PYRIDINE-3-CARBONYL)-2,4-DIFLUORO-PHÉNYL]-2,5-DIFLUORO-BENZÈNESULFONAMIDE,LE N-[3-(5-CYANO-1H-PYRROLO[2,3-B] PYRIDINE-3-CARBONYL)-2,4-DIFLUORO-PHÉNYL]-3-FLUORO-BENZÈNESULFONAMIDE, LE PYRROLIDINE-1-ACIDE SULFONIQUE [3-(5-CYANO-1H-PYRROLO[2,3-B] PYRIDINE-3-CARBONYL)-2,4-DIFLUORO-PHÉNYL]-AMIDE, LE N,N-DIMÉTHYLAMINO-ACIDE SULFONIQUE [3-(5-CYANO-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL)-2,4-DIFLUORO-PHÉNYL]-AMIDE, ET LEURS SELS, LEURS FORMULATIONS, LEURS CONJUGUÉS, LEURS DÉRIVÉS, LEURS FORMES ET LEURS UTILISATIONS. DANS CERTAINS ASPECTS ET MODES DE RÉALISATION, LES COMPOSÉS SELON L'INVENTION OU LEURS SELS, LEURS FORMULATIONS, LEURS CONJUGUÉS, LEURS DÉRIVÉS, ET LEURS FORMES SONT ACTIFS SUR AU MOINS UNE PROTÉINE KINASE RAF. L'INVENTION CONCERNE ÉGALEMENT LEURS PROCÉDÉS D'UTILISATION POUR TRAITER DES MALADIES ET DES ÉTATS, Y COMPRIS DES MALADIES ET ÉTATS ASSOCIÉS À L'ACTIVITÉ DES PROTÉINES KINASES RAF, NOTAMMENT LE MÉLANOME, LE GLIOME, LE CANCER COLORECTAL, LE CANCER DE LA THYROÏDE, LE CANCER DU POUMON, LE CANCER DE L'OVAIRE, LE CANCER DE LA PROSTATE, ET LE CANCER DU TRACTUS BILIAIRE.
MA34228A 2009-03-11 2010-03-10 Dérivés de pyrrolo [2,3-b]pyridine pour l'inhibition des kinases raf MA33181B1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US15940009P 2009-03-11 2009-03-11
US15939009P 2009-03-11 2009-03-11
US15939509P 2009-03-11 2009-03-11
US15940609P 2009-03-11 2009-03-11
US15939209P 2009-03-11 2009-03-11
US15939609P 2009-03-11 2009-03-11
US15940209P 2009-03-11 2009-03-11
PCT/US2010/026816 WO2010104945A1 (fr) 2009-03-11 2010-03-10 Dérivés de pyrrolo [2, 3-b] pyridine pour l'inhibition des kinases raf

Publications (1)

Publication Number Publication Date
MA33181B1 true MA33181B1 (fr) 2012-04-02

Family

ID=42199540

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34228A MA33181B1 (fr) 2009-03-11 2010-03-10 Dérivés de pyrrolo [2,3-b]pyridine pour l'inhibition des kinases raf

Country Status (23)

Country Link
US (1) US8901301B2 (fr)
EP (1) EP2406259A1 (fr)
JP (1) JP2012520307A (fr)
KR (1) KR101663339B1 (fr)
CN (1) CN102421776A (fr)
AR (1) AR075812A1 (fr)
AU (1) AU2010224245B2 (fr)
BR (1) BRPI1011515A2 (fr)
CA (1) CA2755045A1 (fr)
CO (1) CO6620074A2 (fr)
CR (1) CR20110476A (fr)
EC (1) ECSP11011313A (fr)
MA (1) MA33181B1 (fr)
MX (1) MX2011009489A (fr)
MY (1) MY161861A (fr)
NI (1) NI201100168A (fr)
NO (1) NO20111241A1 (fr)
PE (1) PE20120184A1 (fr)
RU (1) RU2011141123A (fr)
SG (2) SG174257A1 (fr)
TW (1) TW201036973A (fr)
WO (1) WO2010104945A1 (fr)
ZA (1) ZA201106599B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
WO2009143018A2 (fr) 2008-05-19 2009-11-26 Plexxikon, Inc. Composés et procédés de modulation des kinases, et indications associées
JP2012509342A (ja) 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
EA022924B1 (ru) 2009-04-03 2016-03-31 Ф.Хоффманн-Ля Рош Аг ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
NZ629615A (en) 2009-11-06 2016-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
PE20121335A1 (es) 2009-11-18 2012-10-12 Plexxikon Inc Compuestos derivados de amida como inhibidores de raf cinasas
RU2012131373A (ru) * 2009-12-23 2014-01-27 Плексксикон, Инк. Соединения и способы модулирования киназы, а также показания для такого модулирования
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
EP2569315A1 (fr) 2010-05-14 2013-03-20 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
EP2646054A4 (fr) 2010-12-02 2015-03-04 Univ Pittsburgh Méthodes de traitement d'une tumeur au moyen d'un anticorps qui se lie spécifiquement à grp94
SI2672967T1 (sl) * 2011-02-07 2018-12-31 Plexxikon Inc. Spojine in postopki za kinazno modulacijo in indikacije zanjo
WO2012149547A1 (fr) 2011-04-28 2012-11-01 Duke University Procédés de traitement d'hémoglobinopathies
HK1199713A1 (en) 2011-05-17 2015-08-14 普莱希科公司 Kinase modulation and indications therefor
US9988687B2 (en) * 2011-09-20 2018-06-05 The George Washington Univeristy Companion diagnostics for cancer and screening methods to identify companion diagnostics for cancer based on splicing variants
EP2757885B1 (fr) 2011-09-21 2017-03-15 Neupharma, Inc. Entités chimiques, compositions, et procédés spécifiques
US20130172375A1 (en) 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) * 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
TWI601725B (zh) 2012-08-27 2017-10-11 加拓科學公司 取代的氮雜吲哚化合物及其鹽、組合物和用途
MX2015002887A (es) 2012-09-06 2015-07-06 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
US9861685B2 (en) 2012-11-20 2018-01-09 Duke University Methods of treating hemoglobinopathies
WO2014100620A2 (fr) 2012-12-21 2014-06-26 Plexxikon Inc. Composés et procédés pour la modulation de kinase, et indications associées
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
PT2970265T (pt) 2013-03-15 2018-10-23 Plexxikon Inc Compostos heterocíclicos e suas utilizações
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
TW201533028A (zh) 2013-05-30 2015-09-01 Plexxikon Inc 用於激酶調節之化合物及其適應症
WO2015108907A2 (fr) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions et méthodes pour l'identification, l'évaluation, la prévention, et le traitement d'un mélanome à l'aide d'isoformes de pd-l1
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AU2015318233B2 (en) 2014-09-15 2020-03-12 Plexxikon Inc. Heterocyclic compounds and uses thereof
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
HRP20201383T1 (hr) 2015-05-06 2020-11-27 Plexxikon Inc. Kruti oblici spoja za moduliranje kinaza
EP3292122B1 (fr) 2015-05-06 2020-01-15 Plexxikon Inc. Synthèse de dérivés 1h-pyrrolo[2,3-b]pyridine qui modulent les kinases
WO2017019804A2 (fr) 2015-07-28 2017-02-02 Plexxikon Inc. Composés et procédés de modulation des kinases, et indications associées
JP6863970B2 (ja) 2015-09-21 2021-04-21 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． ヘテロ環式化合物およびそれらの使用
KR20180086247A (ko) 2015-12-07 2018-07-30 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법과 이들에 대한 징후
ES2904615T3 (es) 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
WO2018136202A2 (fr) 2016-12-23 2018-07-26 Plexxikon Inc. Composés et procédés pour la modulation de cdk8, et indications associées
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
US10577366B2 (en) 2017-03-20 2020-03-03 Plexxikon Inc. Crystalline forms of a compound that inhibits bromodomain
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
CN110944670B (zh) 2017-07-25 2023-03-10 普莱希科公司 调制激酶的化合物的制剂
CA3079029A1 (fr) 2017-10-13 2019-04-18 Plexxikon Inc. Formes solides d'un compose pour la modulation de kinases
EP3700574B1 (fr) 2017-10-27 2024-08-28 Plexxikon Inc. Formulation d'un composé modulant les kinases
ES3000465T3 (en) 2018-01-31 2025-02-28 Heparegenix Gmbh Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US11149011B2 (en) 2018-03-20 2021-10-19 Plexxikon Inc. Compounds and methods for IDO and TDO modulation, and indications therefor
GB201809460D0 (en) * 2018-06-08 2018-07-25 Crt Pioneer Fund Lp Salt form
US11731968B2 (en) 2018-06-21 2023-08-22 Heparegenix Gmbh Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
JP7365393B2 (ja) 2018-07-16 2023-10-19 ヘパリジェニックス ゲーエムベーハー 肝再生促進又は肝細胞死の抑制もしくは防止のためのプロテインキナーゼ阻害剤
BR112021019957A2 (pt) 2019-04-09 2021-12-07 Plexxikon Inc Azinas condensadas para modulação de ep300 ou cbp e indicações da mesma
US12509444B2 (en) 2019-12-06 2025-12-30 Plexxikon Inc. Compounds and methods for CD73 modulation and indications therefor
JP7639008B2 (ja) 2020-01-15 2025-03-04 ヘパリジェニックス ゲーエムベーハー 肝再生促進又は肝細胞死の抑制もしくは防止のためのプロテインキナーゼ阻害剤
TW202206422A (zh) 2020-04-23 2022-02-16 美商普雷辛肯公司 用於ｃｄ７３調節之化合物及方法及其適應症
US11739088B2 (en) 2020-04-29 2023-08-29 Plexxikon Inc. Synthesis of heterocyclic compounds
CA3192047A1 (fr) 2020-08-21 2022-02-24 Plexxikon Inc. Therapies anticancereuses a base de medicaments combinatoires

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2277551E (pt) 2002-09-06 2013-08-22 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
MY153898A (en) * 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa

Also Published As

Publication number Publication date
TW201036973A (en) 2010-10-16
WO2010104945A1 (fr) 2010-09-16
US8901301B2 (en) 2014-12-02
NO20111241A1 (no) 2011-09-28
AR075812A1 (es) 2011-04-27
MX2011009489A (es) 2011-10-11
EP2406259A1 (fr) 2012-01-18
BRPI1011515A2 (pt) 2016-03-29
CA2755045A1 (fr) 2010-09-16
SG174257A1 (en) 2011-10-28
PE20120184A1 (es) 2012-03-28
RU2011141123A (ru) 2013-04-20
AU2010224245B2 (en) 2016-07-21
CN102421776A (zh) 2012-04-18
SG10201402977WA (en) 2014-09-26
AU2010224245A1 (en) 2011-09-29
MY161861A (en) 2017-05-15
NI201100168A (es) 2012-01-11
CR20110476A (es) 2012-01-04
KR101663339B1 (ko) 2016-10-06
KR20110125670A (ko) 2011-11-21
ECSP11011313A (es) 2011-10-31
CO6620074A2 (es) 2013-02-15
JP2012520307A (ja) 2012-09-06
ZA201106599B (en) 2014-02-26
US20100286178A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
MA33181B1 (fr) Dérivés de pyrrolo [2,3-b]pyridine pour l'inhibition des kinases raf
WO2007120883A3 (fr) Compositions et leurs utilisations sur l'hepcidine
TW200616632A (en) Compounds modulating c-kit activity and uses therefor
ATE485265T1 (de) 5-substituierte-2-phenylaminobenzamide als mek- inhibitoren
NO20071843L (no) Substituerte anilinderivater
NO20075111L (no) Farmasoytisk sammensetning
WO2006031291A3 (fr) Nouvelle classe de molecules a base de proteines therapeutiques
MA33811B1 (fr) Composés et méthodes utilisés pour la modulation kinases et indications à cet effet
NO20076659L (no) Pyrrolo(2,3-B)pyridinderivater som protein kinase inhibitorer
MY141196A (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
EP2131848A4 (fr) Compositions et methodes de potentialisation de l'activite de molecules biologiquement actives
NO2008019I1 (no) N-[2-(dietylamino)etyl]-5-[(Z)-(5-fluoro-2-okso-L,2-dihydro-3H-indol-3-yliden)metyl]-2,4-dimetyl-LH-pyrrol-3-karboksamid (sunitinib),samt farmasoeytisk akseptable salter
EA200300793A1 (ru) Производные 3-(4-амидопиррол-2-илметилиден)-2-индолинона в качестве ингибиторов протеинкиназ
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
WO2005082341A3 (fr) Agents non peptidyl a activite de type phsp20 et utilisations correspondantes
EP2123649A4 (fr) Dérivés de 3-pyrrolo-cyclohexylène-2-dihydro-indolinone et utilisations de ceux-ci
NO20071438L (no) 4-arylspirosykloalky 1-2-aminopyrimidinkarboksamid KCNQ kaliumkanal modulerende forbindelser
WO2003063787A3 (fr) Analogues non steroidiens de 2-methoxyestradiol
WO2006047032A3 (fr) Composes indole convenant comme agents selectifs par rapport a la serotonine
ATE478876T1 (de) Thienopyridine als allosterische verstärker des m4-muscarinrezeptors
MA28366A1 (fr) Derives de piperidinylalkylcarbamates, leur preparation et leur application comme inhibiteurs de l'enzyme faah
EP2076132A4 (fr) Sel de l'acide p-toluène sulfonique de 5-amino-3-(2'-0-acétyl-3'-désoxy-beta -d-ribofuranosyl)-3h-thiazole [4, 5-d]pyrimidine-2-one et ses procédés de préparation
NO20081713L (no) Pyrimidinderivater og deres anvendelse som KCNQ-kaliumkanalapnere
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение